Click here to get full coverage on Evogene Reports Third Quarter 2025 Financial Results - PR Newswire

Evogene Reports Third Quarter 2025 Financial Results  PR Newswire

Evogene Reports Third Quarter 2025 Financial Results - PR Newswire

Click here to get full coverage on Evogene Ltd (EVGN) Q4 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue Decline By GuruFocus - Investing.com Canada

Evogene Ltd (EVGN) Q4 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue Decline By GuruFocus  Investing.com Canada

Evogene Ltd (EVGN) Q4 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue Decline By GuruFocus - Investing.com Canada

Click here to get full coverage on AI-designed drugs and herbicides: inside Evogene’s new focus - Stock Titan

AI-designed drugs and herbicides: inside Evogene’s new focus  Stock Titan

AI-designed drugs and herbicides: inside Evogene’s new focus - Stock Titan

Click here to get full coverage on EVOGENE ($EVGN) Releases Q4 2025 Earnings - Quiver Quantitative

EVOGENE ($EVGN) Releases Q4 2025 Earnings  Quiver Quantitative

EVOGENE ($EVGN) Releases Q4 2025 Earnings - Quiver Quantitative

Click here to get full coverage on Evogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring 2026 - Sahm

Evogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring 2026  Sahm

Evogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring 2026 - Sahm

Click here to get full coverage on Evogene (EVGN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan

Evogene (EVGN) Stock Analysis Report | Ratings, Financials & Performance  Benzinga Japan

Evogene (EVGN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan

Click here to get full coverage on Evogene: Q4 Earnings Snapshot - KTVB

Evogene: Q4 Earnings Snapshot - KTVB

Click here to get full coverage on Why Did EVGN Shares Drop More Than 14% Today? - Stocktwits

Why Did EVGN Shares Drop More Than 14% Today?  Stocktwits

Why Did EVGN Shares Drop More Than 14% Today? - Stocktwits

Click here to get full coverage on Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release - PR Newswire

Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release  PR Newswire

Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release - PR Newswire

Click here to get full coverage on AI drug designer Evogene slashes costs as it sells side businesses - Stock Titan

AI drug designer Evogene slashes costs as it sells side businesses  Stock Titan

AI drug designer Evogene slashes costs as it sells side businesses - Stock Titan

Click here to get full coverage on Evogene sets March 5 date to reveal Q4 and full-year 2025 numbers - Stock Titan

Evogene sets March 5 date to reveal Q4 and full-year 2025 numbers  Stock Titan

Evogene sets March 5 date to reveal Q4 and full-year 2025 numbers - Stock Titan

Click here to get full coverage on Can new AI-designed drugs repair nerve damage from multiple sclerosis? - Stock Titan

Can new AI-designed drugs repair nerve damage from multiple sclerosis?  Stock Titan

Can new AI-designed drugs repair nerve damage from multiple sclerosis? - Stock Titan

Click here to get full coverage on Evogene Announces Completion of First-In-Class Foundation Model for Generative Molecule Design, Developed in Collaboration with Google Cloud - PR Newswire

Evogene Announces Completion of First-In-Class Foundation Model for Generative Molecule Design, Developed in Collaboration with Google Cloud  PR Newswire

Evogene Announces Completion of First-In-Class Foundation Model for Generative Molecule Design, Developed in Collaboration with Google Cloud - PR Newswire

Click here to get full coverage on Evogene Reports First Quarter 2025 Financial Results - PR Newswire

Evogene Reports First Quarter 2025 Financial Results  PR Newswire

Evogene Reports First Quarter 2025 Financial Results - PR Newswire

Click here to get full coverage on Evogene to Present at H.C. Wainwright 27th Annual Global Investment Conference in New York - PR Newswire

Evogene to Present at H.C. Wainwright 27th Annual Global Investment Conference in New York  PR Newswire

Evogene to Present at H.C. Wainwright 27th Annual Global Investment Conference in New York - PR Newswire

Click here to get full coverage on Evogene and Queensland University of Technology (QUT) Announce a Collaboration to Advance AI-Driven Cancer Therapeutics - PR Newswire

Evogene and Queensland University of Technology (QUT) Announce a Collaboration to Advance AI-Driven Cancer Therapeutics  PR Newswire

Evogene and Queensland University of Technology (QUT) Announce a Collaboration to Advance AI-Driven Cancer Therapeutics - PR Newswire

Click here to get full coverage on New AI-led push targets lung cancers that resist chemo and drugs - Stock Titan

New AI-led push targets lung cancers that resist chemo and drugs  Stock Titan

New AI-led push targets lung cancers that resist chemo and drugs - Stock Titan

Click here to get full coverage on How Evogene and Google Cloud use AI agents to speed drug and crop discovery - Stock Titan

How Evogene and Google Cloud use AI agents to speed drug and crop discovery  Stock Titan

How Evogene and Google Cloud use AI agents to speed drug and crop discovery - Stock Titan

Click here to get full coverage on Evogene raises $3.4M by cutting warrant price to $1 each - Stock Titan

Evogene raises $3.4M by cutting warrant price to $1 each  Stock Titan

Evogene raises $3.4M by cutting warrant price to $1 each - Stock Titan

Click here to get full coverage on Evogene Announces a Warrant Inducement Transaction for Approximately $3.4 Million of Gross Proceeds - PR Newswire

Evogene Announces a Warrant Inducement Transaction for Approximately $3.4 Million of Gross Proceeds  PR Newswire

Evogene Announces a Warrant Inducement Transaction for Approximately $3.4 Million of Gross Proceeds - PR Newswire

Click here to get full coverage on EVGN: Strategic refocus and cost reductions narrowed net loss to $7.8M despite lower revenue in 2025 - TradingView

EVGN: Strategic refocus and cost reductions narrowed net loss to $7.8M despite lower revenue in 2025  TradingView

EVGN: Strategic refocus and cost reductions narrowed net loss to $7.8M despite lower revenue in 2025 - TradingView

Click here to get full coverage on Evogene Appoints Prof. John Irwin and Prof. Dan Major to its Scientific Advisory Board - PR Newswire

Evogene Appoints Prof. John Irwin and Prof. Dan Major to its Scientific Advisory Board  PR Newswire

Evogene Appoints Prof. John Irwin and Prof. Dan Major to its Scientific Advisory Board - PR Newswire

Click here to get full coverage on Evogene Earnings Review: Q4 Summary - Benzinga

Evogene Earnings Review: Q4 Summary  Benzinga

Evogene Earnings Review: Q4 Summary - Benzinga

Click here to get full coverage on Evogene Ltd (EVGN) Q2 2025 Earnings Call Highlights: Revenue Growth and Strategic Shifts Amid ... - Yahoo Finance

Evogene Ltd (EVGN) Q2 2025 Earnings Call Highlights: Revenue Growth and Strategic Shifts Amid ...  Yahoo Finance

Evogene Ltd (EVGN) Q2 2025 Earnings Call Highlights: Revenue Growth and Strategic Shifts Amid ... - Yahoo Finance

Click here to get full coverage on AI-designed drugs take aim at inflammatory diseases affecting millions - Stock Titan

AI-designed drugs take aim at inflammatory diseases affecting millions  Stock Titan

AI-designed drugs take aim at inflammatory diseases affecting millions - Stock Titan

Click here to get full coverage on Evogene: Q4 Earnings Snapshot - theheraldreview.com

Evogene: Q4 Earnings Snapshot  theheraldreview.com

Evogene: Q4 Earnings Snapshot - theheraldreview.com

Click here to get full coverage on ICL to Acquire the Activity of Evogene's Subsidiary, Lavie Bio - PR Newswire

ICL to Acquire the Activity of Evogene's Subsidiary, Lavie Bio  PR Newswire

ICL to Acquire the Activity of Evogene's Subsidiary, Lavie Bio - PR Newswire

Click here to get full coverage on Experimental gut bacteria therapy targets kidney and lung cancer - Stock Titan

Experimental gut bacteria therapy targets kidney and lung cancer  Stock Titan

Experimental gut bacteria therapy targets kidney and lung cancer - Stock Titan

Click here to get full coverage on Evogene Ltd. (NASDAQ:EVGN) Q4 2025 Earnings Call Transcript - Insider Monkey

Evogene Ltd. (NASDAQ:EVGN) Q4 2025 Earnings Call Transcript  Insider Monkey

Evogene Ltd. (NASDAQ:EVGN) Q4 2025 Earnings Call Transcript - Insider Monkey

Click here to get full coverage on Evogene Q4 2025 Earnings Call Transcript - MarketBeat

Evogene Q4 2025 Earnings Call Transcript  MarketBeat

Evogene Q4 2025 Earnings Call Transcript - MarketBeat

Click here to get full coverage on An Overview of Evogene's Earnings - Benzinga

An Overview of Evogene's Earnings  Benzinga

An Overview of Evogene's Earnings - Benzinga

Click here to get full coverage on Evogene Schedules Second Quarter 2025 Financial Results Release - PR Newswire

Evogene Schedules Second Quarter 2025 Financial Results Release  PR Newswire

Evogene Schedules Second Quarter 2025 Financial Results Release - PR Newswire

Click here to get full coverage on Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development - PR Newswire

Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development  PR Newswire

Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development - PR Newswire

Click here to get full coverage on Evogene Earnings Call: AI Ambition Meets Cash Reality - The Globe and Mail

Evogene Earnings Call: AI Ambition Meets Cash Reality  The Globe and Mail

Evogene Earnings Call: AI Ambition Meets Cash Reality - The Globe and Mail

Click here to get full coverage on Evogene Financial Results: Quarterly and Annual Report - News and Statistics - IndexBox

Evogene Financial Results: Quarterly and Annual Report - News and Statistics  IndexBox

Evogene Financial Results: Quarterly and Annual Report - News and Statistics - IndexBox

Click here to get full coverage on EVGN Forecast — Price Prediction for 2026. Should I Buy EVGN? - Intellectia AI

EVGN Forecast — Price Prediction for 2026. Should I Buy EVGN?  Intellectia AI

EVGN Forecast — Price Prediction for 2026. Should I Buy EVGN? - Intellectia AI

Click here to get full coverage on Evogene Reshapes AI-Driven Molecule Business With 2025 Results and Strategic Overhaul - TipRanks

Evogene Reshapes AI-Driven Molecule Business With 2025 Results and Strategic Overhaul  TipRanks

Evogene Reshapes AI-Driven Molecule Business With 2025 Results and Strategic Overhaul - TipRanks

Click here to get full coverage on Evogene earnings missed by $0.20, revenue topped estimates - Investing.com

Evogene earnings missed by $0.20, revenue topped estimates  Investing.com

Evogene earnings missed by $0.20, revenue topped estimates - Investing.com

Click here to get full coverage on Evogene Announces Expected Implementation of 1-for-10 Reverse Share Split - PR Newswire

Evogene Announces Expected Implementation of 1-for-10 Reverse Share Split  PR Newswire

Evogene Announces Expected Implementation of 1-for-10 Reverse Share Split - PR Newswire

Click here to get full coverage on Evogene refocuses on AI drug discovery platform ChemPass - Investing.com

Evogene refocuses on AI drug discovery platform ChemPass  Investing.com

Evogene refocuses on AI drug discovery platform ChemPass - Investing.com

Click here to get full coverage on Evogene Details 2025 Strategic Refocus Around ChemPass AI and Core Health, Agriculture Markets - TipRanks

Evogene Details 2025 Strategic Refocus Around ChemPass AI and Core Health, Agriculture Markets  TipRanks

Evogene Details 2025 Strategic Refocus Around ChemPass AI and Core Health, Agriculture Markets - TipRanks

Click here to get full coverage on Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field Trials - PR Newswire

Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field Trials  PR Newswire

Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field Trials - PR Newswire

Click here to get full coverage on Evogene Releases CEO Letter to Shareholders - Sahm

Evogene Releases CEO Letter to Shareholders  Sahm

Evogene Releases CEO Letter to Shareholders - Sahm

Click here to get full coverage on Evogene Announces Completion of Transaction for the Sale of Lavie Bio's Activity to ICL - PR Newswire

Evogene Announces Completion of Transaction for the Sale of Lavie Bio's Activity to ICL  PR Newswire

Evogene Announces Completion of Transaction for the Sale of Lavie Bio's Activity to ICL - PR Newswire

Click here to get full coverage on Evogene Announces Collaboration with Google Cloud to Pioneer Generative AI Foundation Model for Novel Small Molecule Design - PR Newswire

Evogene Announces Collaboration with Google Cloud to Pioneer Generative AI Foundation Model for Novel Small Molecule Design  PR Newswire

Evogene Announces Collaboration with Google Cloud to Pioneer Generative AI Foundation Model for Novel Small Molecule Design - PR Newswire

Click here to get full coverage on Evogene Secures $3.4 Million Through Warrant Inducement Deal - TipRanks

Evogene Secures $3.4 Million Through Warrant Inducement Deal  TipRanks

Evogene Secures $3.4 Million Through Warrant Inducement Deal - TipRanks

Click here to get full coverage on Earnings call transcript: Evogene reports Q3 2025 earnings beat amid restructuring - Investing.com

Earnings call transcript: Evogene reports Q3 2025 earnings beat amid restructuring  Investing.com

Earnings call transcript: Evogene reports Q3 2025 earnings beat amid restructuring - Investing.com

Click here to get full coverage on EverGen Infrastructure Second Quarter 2025 Earnings: CA$0.10 loss per share (vs CA$0.053 loss in 2Q 2024) - simplywall.st

EverGen Infrastructure Second Quarter 2025 Earnings: CA$0.10 loss per share (vs CA$0.053 loss in 2Q 2024)  simplywall.st

EverGen Infrastructure Second Quarter 2025 Earnings: CA$0.10 loss per share (vs CA$0.053 loss in 2Q 2024) - simplywall.st

Click here to get full coverage on Evogene announces warrant inducement deal for $3.4 million - Investing.com

Evogene announces warrant inducement deal for $3.4 million  Investing.com

Evogene announces warrant inducement deal for $3.4 million - Investing.com

Click here to get full coverage on Evogene Appoints Dr. Olga Nissan as Vice President of Business Development to Drive AI-Driven Growth - TipRanks

Evogene Appoints Dr. Olga Nissan as Vice President of Business Development to Drive AI-Driven Growth  TipRanks

Evogene Appoints Dr. Olga Nissan as Vice President of Business Development to Drive AI-Driven Growth - TipRanks

Click here to get full coverage on Evogene Announces Expanded Collaboration with Google Cloud to In - GuruFocus

Evogene Announces Expanded Collaboration with Google Cloud to In  GuruFocus

Evogene Announces Expanded Collaboration with Google Cloud to In - GuruFocus

Click here to get full coverage on Evogene appoints two professors to scientific advisory board - Investing.com

Evogene appoints two professors to scientific advisory board  Investing.com

Evogene appoints two professors to scientific advisory board - Investing.com

Click here to get full coverage on Evogene expands Google Cloud collaboration to enhance AI platform - Investing.com

Evogene expands Google Cloud collaboration to enhance AI platform  Investing.com

Evogene expands Google Cloud collaboration to enhance AI platform - Investing.com

Click here to get full coverage on Why Evogene Ltd. (EVGN) Soared on Monday - Insider Monkey

Why Evogene Ltd. (EVGN) Soared on Monday  Insider Monkey

Why Evogene Ltd. (EVGN) Soared on Monday - Insider Monkey

Click here to get full coverage on Syngenta and Lavie Bio Announce Partnership to Discover and Develop Novel Bio-Insecticide - PR Newswire

Syngenta and Lavie Bio Announce Partnership to Discover and Develop Novel Bio-Insecticide  PR Newswire

Syngenta and Lavie Bio Announce Partnership to Discover and Develop Novel Bio-Insecticide - PR Newswire

Click here to get full coverage on Evogene subsidiary licenses cancer microbiome therapy to Lishan Biotech - Investing.com

Evogene subsidiary licenses cancer microbiome therapy to Lishan Biotech  Investing.com

Evogene subsidiary licenses cancer microbiome therapy to Lishan Biotech - Investing.com

Click here to get full coverage on Evogene earnings missed by $0.20, revenue topped estimates - Investing.com Australia

Evogene earnings missed by $0.20, revenue topped estimates  Investing.com Australia

Evogene earnings missed by $0.20, revenue topped estimates - Investing.com Australia

Click here to get full coverage on Evogene Ag-Seed Division Awarded Prestigious €1.2M Horizon Grant to Develop Oil-Seed Crops with High CO2 Assimilation and Drought Tolerance - PR Newswire

Evogene Ag-Seed Division Awarded Prestigious €1.2M Horizon Grant to Develop Oil-Seed Crops with High CO2 Assimilation and Drought Tolerance  PR Newswire

Evogene Ag-Seed Division Awarded Prestigious €1.2M Horizon Grant to Develop Oil-Seed Crops with High CO2 Assimilation and Drought Tolerance - PR Newswire

Click here to get full coverage on Insider Trends: Can EVGN continue delivering strong returns - Earnings Miss & Smart Swing Trading Techniques - baoquankhu1.vn

Insider Trends: Can EVGN continue delivering strong returns - Earnings Miss & Smart Swing Trading Techniques  baoquankhu1.vn

Insider Trends: Can EVGN continue delivering strong returns - Earnings Miss & Smart Swing Trading Techniques - baoquankhu1.vn

Click here to get full coverage on Evogene's ChemPass AI Tech-Engine is Introduced with New Breakthrough Machine Learning Technology for Target-Protein Discovery - PR Newswire

Evogene's ChemPass AI Tech-Engine is Introduced with New Breakthrough Machine Learning Technology for Target-Protein Discovery  PR Newswire

Evogene's ChemPass AI Tech-Engine is Introduced with New Breakthrough Machine Learning Technology for Target-Protein Discovery - PR Newswire

Click here to get full coverage on AgPlenus Announces Licensing & Collaboration Agreement with Bayer to Develop a New Sustainable Weed Control Solution - PR Newswire

AgPlenus Announces Licensing & Collaboration Agreement with Bayer to Develop a New Sustainable Weed Control Solution  PR Newswire

AgPlenus Announces Licensing & Collaboration Agreement with Bayer to Develop a New Sustainable Weed Control Solution - PR Newswire

Click here to get full coverage on Evogene earnings missed by $0.20, revenue topped estimates - Investing.com UK

Evogene earnings missed by $0.20, revenue topped estimates  Investing.com UK

Evogene earnings missed by $0.20, revenue topped estimates - Investing.com UK

Click here to get full coverage on Evogene earnings missed by $0.20, revenue topped estimates - Investing.com Canada

Evogene earnings missed by $0.20, revenue topped estimates  Investing.com Canada

Evogene earnings missed by $0.20, revenue topped estimates - Investing.com Canada

Click here to get full coverage on Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results - PR Newswire

Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results  PR Newswire

Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results - PR Newswire

Click here to get full coverage on Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025 - PR Newswire

Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025  PR Newswire

Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025 - PR Newswire

Click here to get full coverage on Evogene Schedules Second Quarter 2024 Financial Results Release - Stock Titan

Evogene Schedules Second Quarter 2024 Financial Results Release  Stock Titan

Evogene Schedules Second Quarter 2024 Financial Results Release - Stock Titan

Click here to get full coverage on Evogene Announces Pricing of US$5.5 Million Registered Direct Offering and Concurrent Private Placement - PR Newswire

Evogene Announces Pricing of US$5.5 Million Registered Direct Offering and Concurrent Private Placement  PR Newswire

Evogene Announces Pricing of US$5.5 Million Registered Direct Offering and Concurrent Private Placement - PR Newswire

Click here to get full coverage on Evogene Announces Filing of Annual Report on Form 20-F - PR Newswire

Evogene Announces Filing of Annual Report on Form 20-F  PR Newswire

EVGN

Price Chart

Key Statistics

Technicals

About EVGN

Latest News

Evogene Reports Third Quarter 2025 Financial Results - PR Newswire

Evogene Ltd (EVGN) Q4 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue Decline By GuruFocus - Investing.com Canada

AI-designed drugs and herbicides: inside Evogene’s new focus - Stock Titan

Advanced Charts

Top Gainers

Top Losers